Research
Policy Analysis
Comprehensive research on market dynamics, drug-specific case studies, revenue projections, legal framework, congressional pathway, international precedents, and enforcement mechanisms.
Contents
Section 1
US-China Biotech Competition
China has transformed from a fast-follower to an innovation leader. The competitive gap is closing rapidly, with China now leading in several key metrics. Without policy intervention, the US risks losing biotech leadership within a decade.
Comparative Metrics
| Metric | United States | China |
|---|---|---|
| Biotech Market Size (2024) | $621.5B (35% global) | $74.2B (growing 19.8% CAGR) |
| R&D Growth Rate (2019-2023) | 4.7% annually | 8.9% annually |
| Clinical Trials (2024) | 6,000 | 7,100 |
| Drug Approvals (2019-2023) | 243 | 256 |
| STEM PhDs/year (2025 proj.) | ~40,000 | ~77,000 |
| Patent Applications (2024) | <600K | 1.8M (49% global) |
| Global Licensing Deal Value | — | $50B+ (30% of global, up from 3%) |
Harvard Belfer Center: "Out of five critical tech sectors, China has the most immediate opportunity to overtake the United States in biotechnology."
Supply Chain Vulnerabilities
80%
Generic API supply controlled by China
39.9%
Critical pharma inputs from China (by volume)
99%
US prednisone imports from China
320+
Essential medicines on shortage list (Sept 2024)
Sources: Morgan Stanley, Harvard Belfer Center, USCC 2025 Report, Atlantic Council, WIPO
Section 2
Drug Case Studies & 10% Impact
Detailed analysis of major Chinese-origin drugs on the US market and in late-stage pipelines. Combined peak annual reinvestment obligation: $733M - $1.16B.
BeiGene
BRUKINSA (zanubrutinib)
BTK inhibitor for B-cell malignancies. First Chinese-developed drug to reach blockbuster status in US. Market leader in new CLL patient starts.
| 2024 US Revenue | $2.0 billion (106% YoY growth) |
| Projected US Peak | $3.0-3.5 billion (by 2030) |
| 10% at 2024 Revenue | $200M annually |
| 10% at Peak | $300-350M annually |
Sources: BeiGene Q4 2024 financials, GlobalData
Legend Biotech / J&J
CARVYKTI (ciltacabtagene autoleucel)
CAR-T therapy for multiple myeloma. J&J paid $350M upfront to Legend Biotech in 2017. 50/50 profit split globally. Manufacturing scaled to 10,000 doses/year by 2025.
| 2024 Global Revenue | $963M (Legend share ~$482M) |
| J&J Peak Guidance | $5 billion+ (Visible Alpha: $7.2B by 2030) |
| 10% at Current (Legend share) | $48M annually |
| 10% at Peak (Legend share) | $250-360M annually |
Sources: J&J investor guidance, Visible Alpha, Legend Biotech filings
Bristol Myers Squibb / SystImmune
BL-B01D1 (izalontamab brengitecan)
First-in-class EGFRxHER3 bispecific ADC. $8.4 billion deal ($800M upfront). Breakthrough Therapy Designation for EGFR-mutated NSCLC. Co-development in US.
| Deal Value | $8.4 billion total ($800M upfront) |
| Projected US Peak | $3-5 billion |
| 10% at Peak (SystImmune share) | $150-250M annually |
Sources: BMS/SystImmune deal announcement, FDA BTD
Summit Therapeutics / Akeso
Ivonescimab (PD-1/VEGF bispecific)
Beat Keytruda in head-to-head trial for EGFR-mutated NSCLC. $5 billion deal with Akeso ($500M upfront). AstraZeneca reportedly offered $15B.
| Deal Value | $5 billion (low double-digit royalties to Akeso) |
| GlobalData Projection | $1.7B global by 2030; analysts: up to $3B |
| 10% on Akeso Royalties | ~$18M annually |
| 10% on Total US Revenue | $150-200M annually |
Sources: Summit/Akeso deal terms, GlobalData, Clinical Trials Arena
Merck / LaNova
LM-299 / MK-2010 (PD-1/VEGF bispecific)
Exclusive global license to Merck. Competes directly with ivonescimab. $588M upfront, $300M tech transfer milestone.
| Deal Value | $3.3 billion total |
| Projected US Peak | $1.5-3 billion |
| 10% on LaNova Royalties | $15-45M annually |
Sources: Merck/LaNova deal announcement
Aggregate 10% Reinvestment at Peak
Five drugs combined: $733M to $1.16B annually. This represents ~2× BARDA's annual budget from just five drugs.
Section 3
Revenue Projections
| Year | US Revenue | 10% Levy | Comparisons |
|---|---|---|---|
| 2024 | ~$3B | $300M | BRUKINSA + CARVYKTI dominant |
| 2025 | $5B | $500M | 0.3× PDUFA |
| 2027 | $13B | $1.3B | ~1× PDUFA |
| 2030 | $28B | $2.8B | 2× PDUFA, 2.8× BARDA |
| 10-year | $250B+ | $25B+ | Cumulative |
Assumptions: 35% CAGR (consistent with 2020-2024 deal trends), oncology 65% of revenue, major pipeline drugs achieve commercial success.
Morgan Stanley Projections: Annual revenue from China-originated drugs to reach $34B by 2030 and $220B by 2040. FDA approvals from Chinese-origin drugs expected to grow from 5% to 35% by 2040.
Section 4
Congressional Pathway
Committee Jurisdiction
| Committee | Chair | Role |
|---|---|---|
| House Ways & Means | Jason Smith (R-MO) | Tax/revenue provisions |
| House Energy & Commerce | Brett Guthrie (R-KY) | FDA authority, drug regulation |
| Senate Finance | Mike Crapo (R-ID) | Tax provisions, Medicare drug policy |
| Senate HELP | Bill Cassidy (R-LA) | FDA regulation, research policy |
| House Select on CCP | John Moolenaar (R-MI) | China competition framing |
Potential Sponsors (BIOSECURE Champions)
House
- • Raja Krishnamoorthi (D-IL) — BIOSECURE co-author
- • John Moolenaar (R-MI) — CCP Committee Chair
- • Buddy Carter (R-GA) — American-Made Medicines Caucus
Senate
- • Gary Peters (D-MI) — Lead BIOSECURE sponsor
- • Bill Hagerty (R-TN) — BIOSECURE co-sponsor
- • Bill Cassidy (R-LA) — HELP Chair, physician
Legislative Vehicles
| Vehicle | Viability | Notes |
|---|---|---|
| FY2027 NDAA | HIGH | BIOSECURE included in FY2026 NDAA; proven pathway |
| PDUFA VIII Reauthorization | HIGH | Must-pass by Sept 2027; deadline pressure |
| Standalone Bill | MODERATE | Requires bipartisan coalition |
| Budget Reconciliation | CONDITIONAL | If structured as tax/fee with revenue impact |
BIOSECURE Precedent
House voted 306-81 in favor. Signed December 2025 as part of NDAA. Establishes clear precedent for China-specific biotech restrictions.
Section 5
International Precedents
Several countries have implemented policies linking drug pricing or market access to domestic R&D investment. Germany's Medical Research Act is the most directly relevant model.
Germany: Medical Research Act (2024)
Passed July 2024. Explicitly links drug pricing benefits to German R&D investment.
Requirements:
- • Permanent, active research department in Germany
- • Ongoing projects with German research institutions
- • Clinical trials must include ≥5% German patients for extended pricing
Benefits:
- • Extended favorable pricing (3+ years)
- • Confidential reimbursement prices (prevents reference pricing)
- • Companies without German R&D are excluded from confidential pricing
South Korea: 27% Local Ingredient Premium (2025)
April 2025 policy explicitly designed to reduce supply chain vulnerabilities.
- • Up to 27% price premium for essential medicines using locally sourced ingredients
- • Part of Bio-5 coalition with US, EU, India, Japan
- • Target: Double pharmaceutical exports to $16B by 2027
UK: VPAG Clawback (2024-2028)
Voluntary scheme requiring pharma to pay back percentage of NHS branded drug spending.
- • 2025 rate: 22.9% for newer medicines (23.5% with R&D component)
- • Generated ~£3.5B in 2024
- • Two-tier system protects innovation incentives for newer drugs
France: Safeguard Clause + CIR Tax Credit
Combined spending cap and R&D incentive.
- • Clawbacks when industry sales exceed threshold (EUR 27.25B for 2025)
- • Record EUR 1.4B clawback in 2022
- • CIR: 30% R&D tax credit up to EUR 100M (vs ~6-8% US credit)
| Country | Mechanism | Transferability to US |
|---|---|---|
| Germany | R&D requirement for pricing benefits | HIGH |
| South Korea | 27% premium for local ingredients | HIGH |
| UK | Tiered clawback system | MEDIUM |
| France | Enhanced R&D tax credit | MEDIUM |
Section 6
Fund Allocation Recommendations
Based on analysis of BARDA, NIH, ARPA-H, and private models. Recommended structure for a $2.5B annual fund.
Portfolio Allocation
| Category | % Budget | Annual Amount | Rationale |
|---|---|---|---|
| Clinical Trials | 30% | $750M | Largest cost driver |
| Early-Stage Research | 25% | $625M | Address "valley of death" |
| Translational Research | 20% | $500M | Bridge basic to clinical |
| Manufacturing/Infrastructure | 15% | $375M | Domestic capacity |
| Workforce Development | 5% | $125M | Training, geographic expansion |
| Administration | 5% | $125M | Capped overhead |
Governance Structure
15-Member Board
- • 5 independent scientists
- • 3 patient/public health advocates
- • 2 manufacturing experts
- • 2 former government officials
- • 2 regional representatives
- • 1 bioethicist
Anti-Capture Protections
- • 4-year term limits, non-renewable
- • No compensation beyond expenses
- • 2-year industry cooling-off period
- • Public disclosure of all decisions
- • Independent Inspector General
ARPA-H Model Lessons
Tenure-limited program managers with high autonomy. Milestone-based contracts. OTAs for speed with non-traditional partners. 60-180 day award timelines.
Section 7
Enforcement Mechanisms
Three-layer enforcement modeled on proven mechanisms: PDUFA-style market access denial, IRA-style excise tax, and FCA-style whistleblower provisions.
IRA Excise Tax Precedent
| Days Non-Compliant | Tax Rate | Effective Penalty |
|---|---|---|
| 1-90 days | 65% | 185% of price |
| 91-180 days | 75% | 300% of price |
| 181-270 days | 85% | 567% of price |
| 270+ days | 95% | 1,900% of price |
JCT estimated this would raise "no revenue" because no rational company would accept such rates. The IRA mechanism makes compliance economically mandatory without being a formal mandate.
PDUFA Fee Model
Near-100% compliance because no fee payment = no application review. Applications are deemed "Unacceptable for Filing" within 10 days if fees unpaid. Affiliate liability prevents subsidiary evasion.
Recommended Penalty Structure for CHINA PAYS
| Violation | Penalty | Additional Consequence |
|---|---|---|
| Underreporting R&D | 25% of underpayment | 3-year enhanced audit |
| False certification | $50K per statement + 3× damages | FCA liability |
| Repeated non-compliance | Escalating penalties | FDA debarment consideration |
| Fraud | Criminal referral | OIG exclusion from federal programs |
Whistleblower Incentives (FCA Model)
FCA recovered $6.8B in FY2025—largest in history. $5.3B came from whistleblower-initiated cases. Qui tam provisions with 15-30% awards are essential for enforcement.
Section 8
Legal Framework
WTO Considerations
A China-specific policy could face WTO challenge under GATT Article III (national treatment). However:
- US can invoke Article XXI national security exception
- BIOSECURE Act already names Chinese companies without WTO challenge
- WTO Appellate Body is non-functional; US has blocked panel rulings via appeal
- US-China trade relations are already adversarial; marginal WTO risk is acceptable
Constitutional Analysis
| Challenge | IRA Outcome | CHINA PAYS Posture |
|---|---|---|
| Fifth Amendment Takings | Rejected (Third, Second Circuits) | Stronger—10% is modest vs IRA's 79% cuts |
| Due Process | Rejected—rational basis review | National security rationale easily satisfies |
| First Amendment | Rejected—no compelled speech | Not applicable—purely financial obligation |
| Tax vs Penalty (NFIB) | IRA structure untested | 10% rate, no scienter, IRS collection = tax |
Sources
• Morgan Stanley: China Biotech Research
• Harvard Belfer Center: Tech Competition
• USCC 2025 Annual Report to Congress
• National Security Commission on Emerging Biotech
• GlobalData, IQVIA market reports
• BioPharma Dive deal tracker
• BeiGene, Legend Biotech SEC filings
• Germany Medical Research Act (MFG)
• South Korea Ministry of Health Policy
• UK VPAG Agreement Documents
• France LFSS 2024-2025
• BARDA, NIH, ARPA-H program documents
• IRS Pharmaceutical Audit Guidelines
• DOJ False Claims Act Statistics
• CMS IRA Implementation Guidance
• BIOSECURE Act (P.L. 119-60)